Lisocabtagene Maraleucel Shows Deep, Durable Responses in Patients with Relapsed or Refractory MZL After at Least Two Previous Lines of Systemic Therapy By Ogkologos - February 19, 2026 213 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the marginal zone lymphoma cohort of the TRANSCEND FL study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR FDA Approves Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma November 6, 2025 Dog Finds Woman’s Lost Wedding Ring At The Beach August 18, 2021 New Research in Treating Non-Hodgkin Lymphoma and Predicting the Risk of... January 26, 2023 Withdrawal of the Application to Change the EMA Marketing Authorisation for... December 2, 2022 Load more HOT NEWS From athlete to wig-maker: how cancer changed Maria’s destiny EMA Recommends Granting a Conditional Marketing Authorisation for Loncastuximab Tesirine Intermittent Fasting Lung Adenocarcinoma with Mucinous Histology
